These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 35787704)
1. Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program. Ferrannini G; Rosenthal N; Hansen MK; Ferrannini E Cardiovasc Diabetol; 2022 Jul; 21(1):127. PubMed ID: 35787704 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW J Am Coll Cardiol; 2022 Nov; 80(18):1721-1731. PubMed ID: 36302584 [TBL] [Abstract][Full Text] [Related]
3. Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE. Ferrannini G; Pollock C; Natali A; Yavin Y; Mahaffey KW; Ferrannini E Cardiovasc Diabetol; 2023 Apr; 22(1):100. PubMed ID: 37120538 [TBL] [Abstract][Full Text] [Related]
4. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714 [TBL] [Abstract][Full Text] [Related]
5. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356 [TBL] [Abstract][Full Text] [Related]
6. Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial. Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW Int J Cardiol; 2024 Jan; 395():131444. PubMed ID: 37844669 [TBL] [Abstract][Full Text] [Related]
7. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267 [TBL] [Abstract][Full Text] [Related]
8. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE]. Scheen AJ Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553 [TBL] [Abstract][Full Text] [Related]
9. Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials. Tobe SW; Mavrakanas TA; Bajaj HS; Levin A; Tangri N; Slee A; Neuen BL; Perkovic V; Mahaffey KW; Rapattoni W; Ang FG Diabetes Care; 2024 Mar; 47(3):501-507. PubMed ID: 38252809 [TBL] [Abstract][Full Text] [Related]
10. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Arnott C; Li JW; Cannon CP; de Zeeuw D; Neuen BL; Heerspink HJL; Charytan DM; Agarwal A; Huffman MD; Figtree GA; Bakris G; Chang TI; Feng K; Rosenthal N; Zinman B; Jardine MJ; Perkovic V; Neal B; Mahaffey KW Diabetes Obes Metab; 2021 Jul; 23(7):1652-1659. PubMed ID: 33769679 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549 [TBL] [Abstract][Full Text] [Related]
12. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173 [TBL] [Abstract][Full Text] [Related]
13. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Leiter LA; Forst T; Polidori D; Balis DA; Xie J; Sha S Diabetes Metab; 2016 Feb; 42(1):25-32. PubMed ID: 26575250 [TBL] [Abstract][Full Text] [Related]
14. Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program. Chen X; Hou X; Gao J; Yu X; Zeng W; Lv R; Yang X; Liu Y Diabetes Obes Metab; 2024 Mar; 26(3):878-890. PubMed ID: 38031821 [TBL] [Abstract][Full Text] [Related]
18. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. Li J; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B JACC Heart Fail; 2020 Jan; 8(1):57-66. PubMed ID: 31676303 [TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. Bajaj HS; Brown RE; Bhullar L; Sohi N; Kalra S; Aronson R Diabetes Metab; 2018 Dec; 44(6):493-499. PubMed ID: 30149145 [TBL] [Abstract][Full Text] [Related]
20. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. Vaduganathan M; Sattar N; Xu J; Butler J; Mahaffey KW; Neal B; Shaw W; Rosenthal N; Pfeifer M; Hansen MK; Januzzi JL J Am Coll Cardiol; 2022 Feb; 79(5):432-444. PubMed ID: 35115099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]